Navigation Links
Clinical Data on Eisai's Oncology Pipeline to be Presented at ASCO,Annual Meeting

s, especially cancer patients, throughout the world.

About Eisai Inc.

Eisai Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995 and ranked among the top-20 U.S. pharmaceutical companies (based on retail sales), Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2.6 billion in fiscal year 2006 (year ended March 31, 2007).

Eisai Inc. employs approximately 1,500 people at its headquarters in Woodcliff Lake, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. For more information about Eisai, please visit http://www.eisai.com.

About Eisai Medical Research Inc.

Eisai Medical Research Inc., a U.S. pharmaceutical subsidiary of Eisai Co., Ltd., headquartered in Ridgefield Park, NJ, is focused on clinical drug development of new chemical entities and of new indications for marketed products.

About Morphotek, Inc.

Morphotek(R), Inc., a U.S. subsidiary of Eisai Co., Ltd., was acquired by Eisai in April 2007. Founded in 2000 and located in Exton, PA, Morphotek is a biopharmaceutical company which discovers and develops monoclonal antibodies through the use of proprietary human antibody technology called Human MORPHODOMA(R). Morphotek has assembled a strong pipeline of lead products in the areas of oncology and inflammation and infectious diseases. It has programs in clinical development and in preclinical stage moving towards IND filing. For further information, visit




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference

Post Your Comments:
(Date:11/23/2009)...e-FirstCall/-- CryoLife,Inc. (NYSE: CRY ),animplan...eprocessingcompany,announcedtodaythatitisscheduled...althCareConferenceatTheNewYorkPalaceHotelonDecembe...xecutiveofficerofCryoLife,Inc.,willprovideacorpora...dhostaquestionandanswersessionat4:30p.m.EasternTim...
(Date:11/23/2009)...RNewswire-FirstCall/--WoundManagementTechnologies,...rofspecialtymedicalproducts,announcedthatithasfile...ivemanagementbusinessupdatetoillustratethedevelopm...ncreased33.5%to$102,926vs.Q32008salesof$77,084. ,...27,892vs.Q32008shareholderequityof$(321,257) ,...
(Date:11/23/2009)...Newswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ...partnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcont...goingphase2btrialofRG7128,afirst-in-classnucleosid...hepatitisCvirus(HCV)infection.Thedecisionwasreache...gCommittee(DMC)ofallavailablesafetydatafromthefirs...
Breaking Medicine Technology:CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 1Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 2Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 3Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 4Life Science Leaders Discuss Strategies for Surviving the Financial Crisis at Yankee Public Relations Symposium 12692 5Cerebrospinal fluid shows Alzheimers disease deterioration much earlier 49359 1Cerebrospinal fluid shows Alzheimers disease deterioration much earlier 49359 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 1Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 2Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 3Stroke survivors report loss of sexual desire blurred gender roles anger and fatigue 49357 4
...ment in disease activity through three years...ease in adverse events, malignancies, infections o...ver time -, ROCKVILLE, Md., June 12 Human Genome...he presentation of results,from a long- term Phase...,(belimumab) was associated with sustained improve...
...e-FirstCall/ --,Pharmaceutical company Pharmaxis (...2 month Phase III clinical trial evaluating the sa...asis has completed., This 12-month treatment peri...fficacy trial which has already reported, showing ... clearance. The objective of the open,label extens...
Other Medicine Technology:Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 7Pharmaxis Long-Term Safety Study of Bronchitol Completes 2
(Date:11/24/2009)... Slate and New Markets build on their combined str.... , Baltimore, Md. (PRWEB...latecap.com ), a private equity firm based in Balt...( www.newmarketsvp.com ), a venture capital firm b...at they have acquired Ecoast Sales Solutions, Ltd....
(Date:11/24/2009)... Sinusitis patients life is regularly impacted by ...cs non-invasive nasal sinus treatment with Nasal n...pes of Sinusitis without any limitation or interfe...rs found 82.9% of patients treated with Sinus Dyna...particle diameter of 3.2 µm had a “goo...
(Date:11/24/2009).../PRNewswire-USNewswire/--Newpeer-revieweddatafindi...nsinfectedwithchronichepatitisCvirushavereceivedan...atCongressneedstomoveurgentlyonbipartisanlegislati...veillanceefforts,the NationalViralHepatitisRoundta...congressionalaction,millionsofAmericansinfectedwit...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)... After suffering from women,s hair loss for almost... and she,s sharing her progress and the secret beh...ugh the release of her video diaries which include... her treatment. , (PRWeb ...ferer Zsanett Siklosi has released the video diari...
Breaking Medicine News(10 mins):Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3
... read in its,entirety, "Why Do Drugs Cost So Much?...rHouse -- http://www.authorhouse.com ) may cause ...lief and even amusement., Written by the husband ... why are we so darn sick?" is not just,another bor...
...e/ -- Xinyu Hengdeli Holdings,Limited ("Xinyu Heng...Group"; HKEx: 3389), a leading enterprise engaged ...ernational watch brands in China, announced the,gr...Xinyu Elegant, the Group,s retail arm of high-end ...
...- A study presented at Digestive Disease Week 200...R) CT colonography guidelines recommending that po...onography by applying them to an endoscopic databa...to 9 mm in size and no larger polyps can have repe...
...linois hospital in six clinical,areas, CHICAGO, J... 10 clinical specialties -- six of which make it t...ews & World Report,s 2008,America,s Best Hospitals...ed according to the Top 50 programs,in 16 clinical...
...OD, Calif., July 10 Gov. Arnold Schwarzenegger,En...Lisa Paulsen, MPAA,Chair and CEO Dan Glickman, and...she will announce a major Hollywood anti-smoking i...IF brought,together Paramount Pictures, Sony Pictu...
...e overwhelming, bipartisan,approval to legislation...es--the best outcome possible given the difficult ...CP, president of the American,College of Physician...are more than enough to override a,presidential ve...
Other Medicine News:Health News:'Why Do Drugs Cost So Much? and why are we so darn sick?': New Book Reveals Inner Workings of Big Pharma, Asks Hard Questions About Our Health 2Health News:Grand Opening of Xinyu Elegant's Vacheron Constantin Boutique 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 2Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 3Health News: Digestive Disease Week study examined ACR's guidelines for CT colonography interpretation 4Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 2Health News:Northwestern Memorial Among America's Best Hospitals in 10 Clinical Specialties According to U.S. News' 2008 Rankings 3Health News:ACP applauds Senate to vote to pass H.R. 6331 and avert physician payment cut 2
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
...ction Reagents provide molecular labs a more advan... using our MGB technology, combined with post-PCR ...ble to provide molecular labs more powerful tools ...rganisms or genetic mutations associated with dise...
Medicine Products: